ironwood pharmaceuticals (nasdaq: irwd) is focused on creating medicines that make a difference for patients, building value to earn the continued support of our fellow shareholders, and empowering our passionate team to keep doing these two things again and again as we continue to build a leading gastrointestinal therapeutics company. we discovered, developed and are commercializing a medicine for the treatment of adults suffering from irritable bowel syndrome with constipation (ibs-c) or chronic idiopathic constipation (cic). we are also developing a rich pipeline of programs seeking to address patient needs across the upper and lower gastrointestinal tract. our pipeline priorities include exploring further opportunities for our lead medicine, as well as leveraging our therapeutic expertise in gastrointestinal disorders and our pharmacologic expertise in guanylate cyclases to advance multiple investigational medicines. ironwood was founded in 1998 out of the whitehead institute for b